ANDREA HOLLINGSWORTH: Open Payments
NPI 1780236034 · PROVO, UT. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$573 in 30 payments from 14 companies in 2025. Trend: 2023 $341 · 2024 $342 · 2025 $573
Food & beverage: $573
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 12 | $259 |
| Novo Nordisk Inc | 3 | $55 |
| Lilly USA, LLC | 3 | $44 |
| Neurocrine BioSciences, Inc. | 2 | $41 |
| Corcept Therapeutics | 1 | $22 |
| SANOFI-AVENTIS U.S. LLC | 1 | $21 |
| AstraZeneca Pharmaceuticals LP | 1 | $21 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 1 | $20 |
| Edwards Lifesciences Corporation | 1 | $19 |
| GlaxoSmithKline, LLC. | 1 | $17 |
Products named: VRAYLAR, QULIPTA, UBRELVY, Wegovy, MOUNJARO, INGREZZA, Korlym, TZIELD.
Industry payments across UT — which companies pay providers there.
